An effective modestly intensive re‐induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. (20th April 2018)

• Record Type: Journal Article
• Authors: Kaspers, Gertjan J. L.; Niewerth, Denise; Wilhelm, Bram A. J.; Scholte‐van Houtem, Peggy; Lopez‐Yurda, Marta; Berkhof, Johannes; Cloos, Jacqueline; de Haas, Valerie; Mathôt, Ron A.; Attarbaschi, Andishe; Baruchel, André; de Bont, Eveline S.; Fagioli, Franca; Rössig, Claudia; Klingebiel, Thomas; De Moerloose, Barbara; Nelken, Brigitte; Palumbo, Giuseppe; Reinhardt, Dirk; Rohrlich, Pierre‐Simon; Simon, Pauline; von Stackelberg, Arend; Zwaan, Christian Michel
• Is Part Of: British journal of haematology. Volume 181:Number 4(2018)
• Page Start: 523
• Page End: 527
• Publication Date: 2018-04-20
• Subjects: bortezomib -- childhood leukaemia -- acute leukaemia -- pharmacokinetics -- proteasome inhibitor; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15233
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: This trial explored the efficacy of re‐induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.